Bilaal.Raja
Company record

LUCD  Lucid Diagnostics Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-12 and not restated since.
Healthcare

Scale

Market cap
$193m
Revenue TTM
$5m
Net income TTM
$-52m
Free cash flow
Composite score
Sector rank
#2888

Valuation

P / E
EV / EBITDA
EV / sales
35.4
FCF yield
Yield vs 10-yr
-31.87pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-959.8%
EBITDA margin
-914.8%
ROE
-478.3%
ROIC
-463.8%
Revenue growth
24.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Sales and marketing expenses Sales and marketing expenses consist primarily of salaries and related costs for employees engaged in sales, sales support and marketing activities, as well as the portion of the MSA Fee (as defined in Note 5, Related Party Transactions , to our accompanying audited consolidated financial statements) allocated to sales and marketing expenses, which are principally costs related to PAVmed employees who are performing services for the Company. …Lucid Diagnostics Inc., 10-K, period ended 2025-12-31, filed 2026-03-25

Read the full passage →